News
The World Health Organization now recommends lenacapavir, a twice-yearly injectable HIV prevention drug, especially for high-risk groups. This endorse ...
Lenacapavir has been incredibly promising in trials and now the World Health Organisation have officially recommended the drug for HIV prevention. Smitha Mundasad explains the difference this ...
TANZANIA is among countries expected to benefit from the upcoming rollout of injectable lenacapavir for HIV prevention, following a landmark recommendation by the World Health Organization (WHO).
The global recommendation – issued Monday at the International AIDS Conference in Kigali, Rwanda – comes about a month after ...
The World Health Organisation (WHO) has raised concern over the stagnation of global HIV prevention efforts, announcing ...
Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...
23h
The Kenya Times on MSNWhat Kenyans Should Know About New HIV Treatment InjectionLenacapavir received approval from the U.S. Food and Drug Administration (FDA) in June 2025 and has subsequently been endorsed in the updated World Health Organisation (WHO) guidelines on long-acting ...
16h
allAfrica.com on MSNSA gets R520m to buy twice-a-year anti-HIV jab — but there’s a snagThe money is not nearly enough to put two to four million people per year in South Africa on the lenacapavir jab, and even if it were, the country’s health system won’t be able to roll out the ...
In a session titled, Better meeting the needs of people living with HIV, health experts reminded us that science, care, and human rights must move together if we are to achieve real change.
18h
AllAfrica on MSNAfrica: Scientists, Activists Rally at #IAS2025 to Protect HIV ProgressAs science soars with game-changing HIV tools, a funding crisis threatens to ground progress "We come together at a pivotal ...
Lenacapavir, new twice-yearly HIV injection, raises hope for pill-weary patients. Discordant couples, sex workers hail ‘game ...
15h
Medpage Today on MSNInvestigational Once-Weekly ART Combo Maintained Viral Suppression in HIVAn investigational once-weekly oral antiretroviral therapy (ART) combination effectively maintained viral suppression in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results